A peptide antagonist of the NK1 receptor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Spantide I (trifluoroacetate salt)

Item No. 43079

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
D-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-D-tryptophyl-L-phenylalanyl-D-tryptophyl-L-leucyl-L-leucinamide, trifluoroacetate salt
Synonyms
  • [Arg1,Trp7,9,Leu11] Substance P
  • DADTL
  • SPA I
Molecular Formula
C75H108N20O13 • XCF3COOH
Formula Weight
1497.8
Purity
≥98%
Formulation (Request formulation change)
A solid
Peptide Sequence
rPKPQQwFwLL-NH2
Solubility(Learn about Variance in Solubility)
DMSO: Sparingly soluble: 1-10 mg/mlEthanol: Sparingly soluble: 1-10 mg/mlPBS (pH 7.2): Slightly soluble: 0.1-1 mg/ml
SMILES
O=C(N[C@H](CC1=CNC2=CC=CC=C21)C(N[C@@H](CC3=CC=CC=C3)C(N[C@H](CC4=CNC5=CC=CC=C54)C(N[C@H](C(N[C@@H](CC(C)C)C(N)=O)=O)CC(C)C)=O)=O)=O)[C@@H](NC([C@@H](NC([C@H]6N(C([C@H](CCCCN)NC([C@H]7N(C([C@@H](CCCNC(N)=N)N)=O)CCC7)=O)=O)CCC6)=O)CCC(N)=O)=O)CCC(N)=O.O=C(O)C(F)(F)F
InChi Code
InChI=1S/C75H108N20O13.C2HF3O2/c1-42(2)35-55(64(80)98)89-67(101)56(36-43(3)4)90-69(103)59(39-46-41-85-51-23-11-9-20-48(46)51)93-68(102)57(37-44-17-6-5-7-18-44)91-70(104)58(38-45-40-84-50-22-10-8-19-47(45)50)92-66(100)52(27-29-62(78)96)86-65(99)53(28-30-63(79)97)87-71(105)61-26-16-34-95(61)74(108)54(24-12-13-31-76)88-72(106)60-25-15-33-94(60)73(107)49(77)21-14-32-83-75(81)82;3-2(4,5)1(6)7/h5-11,17-20,22-23,40-43,49,52-61,84-85H,12-16,21,24-39,76-77H2,1-4H3,(H2,78,96)(H2,79,97)(H2,80,98)(H,86,99)(H,87,105)(H,88,106)(H,89,101)(H,90,103)(H,91,104)(H,92,100)(H,93,102)(H4,81,82,83);(H,6,7)/t49-,52+,53+,54+,55+,56+,57+,58-,59-,60+,61+;/m1./s1
InChi Key
YZTGFYJGWVAWPR-BHCZHNAISA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $164

    Add

    10 mg

    $279

    Add

    25 mg

    $656

    Add

    50 mg

    $1,066

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Spantide I is a peptide antagonist of the neurokinin-1 (NK1) receptor (Ki = 177.83 nM).1 It is selective for the NK1 receptor over NK2 and NK3 receptors (Kis = 5,000 and >10,000 nM, respectively). Spantide I induces histamine release from isolated rat mast cells (EC50 = 2.5 µM).2 It inhibits neurokinin B-induced contractions in isolated and perfused guinea pig taenia coli when used at a concentration of 10 µM. Intrathecal administration of spantide I (2 µg/animal) increases the latency to withdrawal in the tail-flick- or hot plate test but also induces hindlimb paralysis in rats.3 Spantide I (36 µg/animal per day for five days) decreases corneal P. aeruginosa levels and polymorphonuclear cell infiltration, reduces corneal Il-1β levels, and increases corneal Il-10 levels in a mouse model of corneal P. aeruginosa infection.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. McLean, S., Ganong, A., Seymour, P.A., et al. Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. J. Pharmacol. Exp. Ther. 267(1), 472-479 (1993).

    2. Håkanson, R., Leander, S., Asano, N., et al. Spantide II, a novel tachykinin antagonist having high potency and low histamine-releasing effect. Regul. Pept. 31(1), 75-82 (1990).

    3. Post, C., and Paulsson, I. Antinociceptive and neurotoxic actions of substance P analogues in the rat’s spinal cord after intrathecal administration. Neurosci. Lett. 57(2), 159-164 (1985).

    4. Hazlett, L.D., McClellan, S.A., Barrett, R.P., et al. Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection. Invest. Ophthalmol. Vis. Sci. 48(2), 797-807 (2006).